CA2487857A1 - Aryl boronate functionalized polymers for treating obesity - Google Patents

Aryl boronate functionalized polymers for treating obesity Download PDF

Info

Publication number
CA2487857A1
CA2487857A1 CA002487857A CA2487857A CA2487857A1 CA 2487857 A1 CA2487857 A1 CA 2487857A1 CA 002487857 A CA002487857 A CA 002487857A CA 2487857 A CA2487857 A CA 2487857A CA 2487857 A1 CA2487857 A1 CA 2487857A1
Authority
CA
Canada
Prior art keywords
polymer
group
substituted
ammonium
straight chained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002487857A
Other languages
English (en)
French (fr)
Inventor
Stephen Randall Holmes-Farley
Harry W. Mandeville, Iii
Pradeep K. Dhal
Chad Cori Huval
Xinhua Li
Steven C. Polomoscanik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2487857A1 publication Critical patent/CA2487857A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/42—Introducing metal atoms or metal-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/44—Preparation of metal salts or ammonium salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/08—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing boron

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002487857A 2001-06-29 2002-07-01 Aryl boronate functionalized polymers for treating obesity Abandoned CA2487857A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30222101P 2001-06-29 2001-06-29
US60/302,221 2001-06-29
US35947302P 2002-02-22 2002-02-22
US60/359,473 2002-02-22
PCT/US2002/020947 WO2003002571A1 (en) 2001-06-29 2002-07-01 Aryl boronate functionalized polymers for treating obesity

Publications (1)

Publication Number Publication Date
CA2487857A1 true CA2487857A1 (en) 2003-01-09

Family

ID=26972846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002487857A Abandoned CA2487857A1 (en) 2001-06-29 2002-07-01 Aryl boronate functionalized polymers for treating obesity

Country Status (6)

Country Link
US (2) US7041280B2 (enExample)
EP (1) EP1404686A1 (enExample)
JP (1) JP2004534887A (enExample)
AU (1) AU2002318470B2 (enExample)
CA (1) CA2487857A1 (enExample)
WO (1) WO2003002571A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291567A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
GB2415193A (en) * 2004-06-19 2005-12-21 F2 Chemicals Ltd Fluorinated arylboronic acids
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
WO2011159161A2 (en) 2010-06-18 2011-12-22 Universiteit Twente Boronated polymers
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
TR201703622A1 (tr) 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
JP7539374B2 (ja) * 2018-09-20 2024-08-23 グライセンド， インコーポレイテッド ボロン酸ポリマーおよび使用方法
CN114423768A (zh) 2019-09-20 2022-04-29 格里森德公司 含取代的苯基硼酸的聚合物及使用方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (enExample) * 1969-12-27 1971-06-29
US3923972A (en) * 1971-10-12 1975-12-02 Monsanto Co Method of lowering blood cholesterol level
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
US4265879A (en) * 1977-09-13 1981-05-05 Monsanto Company Method for controlling blood triglycerides
US4218443A (en) * 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4302450A (en) * 1979-01-15 1981-11-24 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4432968A (en) * 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
US4496722A (en) 1981-05-01 1985-01-29 The Children's Medical Center Corporation Reporter compounds
US4634722A (en) * 1981-05-20 1987-01-06 Syntex (U.S.A.) Inc. Copolymers and hydrogels: process and articles made thereof
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5200183A (en) * 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
GB8819224D0 (en) 1988-08-12 1988-09-14 Merck Patent Gmbh Process for preparation of rod-like compounds
US5089163A (en) * 1989-01-30 1992-02-18 Lever Brothers Company, Division Of Conopco, Inc. Enzymatic liquid detergent composition
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5308766A (en) * 1989-08-29 1994-05-03 The Regents Of The University Of California Hydrolytic enzyme inhibitors/inactivators and methods for using same
WO1991003544A1 (en) * 1989-08-29 1991-03-21 The Regents Of The University Of California Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
DE3930663C1 (en) 1989-09-14 1990-11-15 Merck Patent Gmbh, 6100 Darmstadt, De Cross-coupling metal organic cpds. and e.g. halogen cpds. - includes using transition metal-palladium catalyst and opt. metal alcoholate
US5260310A (en) * 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
EP0478050A1 (en) 1990-09-24 1992-04-01 Unilever N.V. Detergent composition
GB9024775D0 (en) 1990-11-14 1991-01-02 Axis Research Chemical compounds
US5137716A (en) * 1990-11-15 1992-08-11 Weisenfeld Michael S Method of reducing weight in mammals
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
HUT65823A (en) 1991-04-30 1994-07-28 Procter & Gamble Liquid detergents with an aryl boronic acid and process for using thereof
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ZA929351B (en) * 1991-12-11 1993-06-04 Igen Inc Electrochemiluminescent label for DNA assays.
EP0622078B1 (en) * 1992-01-14 1999-09-01 Hisamitsu Pharmaceutical Co., Inc. Cholesterol level depressant
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
JP2667351B2 (ja) * 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
DK0563731T3 (da) * 1992-03-28 1996-03-18 Hoechst Ag Lægemidler indeholdende polyhydromethylenderivater, fremgangsmåde til deres fremstilling og deres anvendelse
CA2096496A1 (en) 1992-05-29 1993-11-30 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5290817A (en) 1992-06-09 1994-03-01 The Du Pont Merck Pharmaceutical Co. Substituted 1-benzylindanes and their use as inhibitors of phospholipase A2
WO1994014803A1 (en) 1992-12-21 1994-07-07 Zeneca Limited Quinuclidine derivatives as squalene synthase inhibitors
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5776951A (en) 1993-06-30 1998-07-07 Glaxo Wellcome Inc. Anti-atherosclerotic diaryl compounds
AU7121394A (en) 1993-07-09 1995-02-06 Borax Consolidated Ltd Boronic acid or borinic acid derivatives as enzyme stabilizers
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
JPH09503773A (ja) 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体
US5414068A (en) * 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
EP0741693B1 (en) 1994-01-27 1999-03-24 Novartis AG Process for the preparation of arylacetic ester derivatives via palladium-catalyzed cross coupling reaction
US5631364A (en) 1994-03-31 1997-05-20 Axis Biochemicals Asa Labelled boronic acid derivatives
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
SI9400289A (en) 1994-07-13 1996-02-29 Ponikvar Jadranka Buturovic A method for preventing blood coagulation in a haemodialysis circuit or haemodialysis analogy procedure in the extra-body circuit.
JPH0859458A (ja) * 1994-08-25 1996-03-05 Zeria Pharmaceut Co Ltd インダン誘導体を含有する高脂血症治療剤
WO1996017833A1 (en) 1994-12-09 1996-06-13 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
FI972896A7 (fi) 1995-01-09 1997-07-08 Novo Nordisk As Nestemäisten entsyymikoostumusten stabilointi
US6008219A (en) 1995-03-27 1999-12-28 Smithkline Beech P.L.C. Bicyclic amine derivatives and their use as anti-psychotic agents
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
WO1996041859A1 (en) 1995-06-13 1996-12-27 Novo Nordisk A/S 4-substituted-phenyl-boronic acids as enzyme stabilizers
US5631371A (en) 1995-11-22 1997-05-20 Bayer Corporation Method for the preparation of substituted 3-(phenylimino)-3H-phenothiazines and phenoxazines
GB9603137D0 (en) 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
US6034129A (en) 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
AU5446098A (en) 1996-11-21 1998-06-10 Lawrence Livermore National Laboratory Detection of biological molecules using boronate-based chemical amplification and optical sensors
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
JP2001526643A (ja) 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
JP2002504122A (ja) 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー ベータラクタマーゼ阻害剤及びその使用方法
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
JP2002510328A (ja) 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US5900233A (en) * 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
CO5011067A1 (es) 1997-11-03 2001-02-28 Novartis Ag Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
WO1999047474A1 (en) 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Coupling reactions with palladium catalysts
AU5235599A (en) 1998-07-31 2000-02-21 Eli Lilly And Company N-substituted sulfonamide derivatives
TR200100471T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
AU759388B2 (en) * 1998-08-14 2003-04-10 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors and chitosan
EP1112262B1 (en) 1998-09-09 2004-08-04 Inflazyme Pharmaceuticals Ltd. Substituted gamma-phenyl-delta-lactones and analogs thereof and uses related thereto
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE19857765A1 (de) 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
WO2000035904A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
BRPI0011172B8 (pt) 1999-04-14 2021-05-25 Pacific Corp derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
JP4507294B2 (ja) 1999-05-27 2010-07-21 チッソ株式会社 ビアリール誘導体の製造方法
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6858592B2 (en) * 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids

Also Published As

Publication number Publication date
WO2003002571A1 (en) 2003-01-09
US7041280B2 (en) 2006-05-09
US20060128663A1 (en) 2006-06-15
EP1404686A1 (en) 2004-04-07
JP2004534887A (ja) 2004-11-18
AU2002318470B2 (en) 2005-09-08
US20030059399A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
EP1404685B1 (en) Aryl boronic acids for treating obesity
AU2002316499A1 (en) Aryl Boronic Acids For Treating Obesity
AU2002318470B2 (en) Aryl boronate functionalized polymers for treating obesity
US6264937B1 (en) Fat-binding polymers
JP2004528332A (ja) 痛風を治療する方法および尿酸を結合する方法
US20060134062A1 (en) Polymeric boronic acid derivatives as lipase inhibitors
AU2002318470A1 (en) Aryl boronate functionalized polymers for treating obesity
AU2002346034A1 (en) Fat-binding polymers
EP1404349A1 (en) Fat-binding polymers
AU774636B2 (en) Fat-binding polymers, optionally combined with lipase inhibitors
US6299868B1 (en) Fat-binding polymers
KR100773625B1 (ko) 지방-결합성 중합체
US7048917B1 (en) Fat-binding polymers
HK1065046B (en) Aryl boronic acids for treating obesity
NZ516554A (en) Fat-binding polymers, optionally combined with lipase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued